Fig. 1: Hazard ratios (HR) for overall survival (OS) with their 95% confidence interval (CI 95%) in main meta-analyses assessing the clinical validity of circulating tumor cells (CTCs), according to the CTC count cut-off; in both early breast cancer (EBC) and metastatic breast cancer (MBC). | npj Breast Cancer

Fig. 1: Hazard ratios (HR) for overall survival (OS) with their 95% confidence interval (CI 95%) in main meta-analyses assessing the clinical validity of circulating tumor cells (CTCs), according to the CTC count cut-off; in both early breast cancer (EBC) and metastatic breast cancer (MBC).

From: Circulating tumor cells in breast cancer: clinical validity and utility

Fig. 1

Analyses are multivariate unless specified otherwise. NCT: neoadjuvant chemotherapy.

Back to article page